Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (campath-1H)-based therapies

Gautam Borthakur, E. Lin, Stefan Faderl, Alessandra Ferrajoli, William Wierda, Francis Giles, Mary L. Browning, Hagop Kantarjian, Michael Keating, Susan O'Brien*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

BACKGROUND. Alemtuzumab (Campath-1H), a monoclonal antibody that targets the CD52 antigen, has been approved for the treatment of fludarabine-refractory chronic lymphocytic leukemia. However, the profound immunosuppression caused by alemtuzumab has been associated with infectious complications. METHODS. The authors report on the incidence and risk factors for development of symptomatic cytomegalovirus reactivation in 113 patients with chronic lymphoproliferative disorders who received alemtuzumab-based therapy. Kaplan-Meier methods were applied to generate survival curves, and the log-rank test was used to assess the difference between groups; in addition, univariate and multivariate Cox proportional hazards models were used to estimate the hazard ratio of death including 95% confidence intervals. RESULTS. Cytomegalovirus reactivation was diagnosed in 25 patients (22%), and most of those patients responded to antiviral therapy. Nine additional patients had asymptomatic cytomegalovirus viremia. CONCLUSIONS. With appropriate therapy, most patients achieved clearance of cytomegalovirus viremia. Low serum albumin was the only factor associated significantly with symptomatic cytomegalovirus reactivation.

Original languageEnglish (US)
Pages (from-to)2478-2483
Number of pages6
JournalCancer
Volume110
Issue number11
DOIs
StatePublished - Dec 1 2007

Keywords

  • Alemtuzumab
  • CD52 antigen
  • Cytomegalovirus reactivation
  • Lymphoproliferative disease

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (campath-1H)-based therapies'. Together they form a unique fingerprint.

Cite this